Welcome to our dedicated page for Stepan SEC filings (Ticker: SCL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stepan Company (NYSE: SCL) SEC filings page on Stock Titan brings together the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, with AI-powered tools to help interpret the details. As a public issuer in the specialty and intermediate chemicals space, Stepan files annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K that describe its surfactants, polymers and specialty products businesses, financial results and governance matters.
In Stepan’s 10-K and 10-Q filings, readers can review segment information for surfactants, polymers and specialty products, along with discussions of sales volumes, selling prices, raw material cost pass-through, product mix and operating income. These reports also cover topics such as the company’s global manufacturing footprint in North and South America, Europe and Asia, and its role as a leading merchant producer of surfactants and supplier of polyurethane polyols for thermal insulation and CASE markets.
Form 8-K current reports provide updates on specific events, including quarterly earnings releases, dividend declarations, executive appointments or departures, board changes and adoption of plans such as the Key Executive Severance Benefit Plan. These filings give timely insight into Stepan’s capital allocation, leadership structure and key corporate actions.
Stock Titan enhances access to Stepan’s filings with AI-generated summaries that highlight the most important points in lengthy documents, helping users quickly understand complex financial and legal language. Real-time updates from EDGAR ensure that new Stepan filings appear promptly, while dedicated views for insider transaction reports (Form 4), proxy statements (Schedule 14A) and other forms allow deeper analysis of executive compensation, ownership changes and governance practices. This page serves as a focused resource for anyone researching SCL through its official SEC record.
Stepan Co ownership filing: The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting that, after an internal realignment effective January 12, 2026, Vanguard and its disaggregated subsidiaries hold 0 shares of Stepan Co common stock, representing 0% of the class. The filing states Vanguard no longer is deemed to beneficially own securities held by those subsidiaries and confirms the reporting group’s voting and dispositive powers are all 0. The form is signed by the Head of Global Fund Administration on 03/27/2026.
Stepan Company has issued its 2026 proxy for the annual meeting on April 28, 2026 at its Northbrook, Illinois headquarters. Stockholders of record at the close of business on March 2, 2026, when 22,690,379 common shares were outstanding, are entitled to vote.
The agenda includes electing three directors (Joaquin Delgado, Corning F. Painter and F. Quinn Stepan, Jr.) to terms expiring in 2029, an advisory vote on executive compensation, and ratification of Deloitte & Touche LLP as independent auditor for 2026.
The board is majority independent, uses a separated Chair/CEO structure, and maintains four fully independent committees. BlackRock and The Vanguard Group beneficially own 14.1% and 11.3% of common stock, respectively, while directors and executives as a group hold 6.6%.
Compensation follows a pay-for-performance philosophy, with base salary less than half of target pay and significant short- and long-term incentives tied to earnings, EBITDA, free cash flow and safety. For 2025, corporate performance produced a 24.5% payout on company-wide metrics and annual bonuses of 15–25% of salary for most NEOs.
The proxy details substantial equity-based long-term incentives, robust stock ownership requirements, an updated clawback policy, an insider trading policy that restricts hedging and short sales, and a new key executive severance plan adopted in November 2025.
Stepan Company executive Richard Finn reported mixed equity transactions tied to restricted stock units (RSUs). On March 3 and 4, 2026, RSUs covering 1,253 and 429 units were settled into an equal number of Stepan common shares per award terms.
To cover tax liabilities on these vestings, Finn disposed of 434 and 149 common shares through tax-withholding transactions at prices of $48.985 and $49.615 per share. He continues to hold additional shares both directly and indirectly through family members and various trusts, as reflected in updated ownership balances.
Stepan Company President & CEO Luis Rojo reported equity award activity involving restricted stock units (RSUs) and common stock on March 3–4, 2026. RSUs were converted into common shares, and a portion of those shares was withheld to cover tax obligations.
On March 3, Rojo exercised 4,455 RSUs into the same number of Stepan common shares at a reference price of $48.985, then delivered 1,306 shares to satisfy tax liability. On March 4, he exercised another 857 RSUs at $49.615, with 252 shares withheld for taxes.
After these transactions, Rojo directly owned 19,451.666 shares of Stepan common stock and held 858 RSUs, with an additional 511.83 shares held indirectly through the ESOP II Trust.
Stepan Company executive Robert Joseph Haire reported equity award activity involving restricted stock units and common stock. On March 3 and 4, 2026, RSUs covering 2,241 shares were converted into Stepan common stock, consistent with the award terms that settle each RSU in one share.
To cover associated tax liabilities on these RSU vestings, Haire disposed of 658 common shares through share withholding transactions coded “F,” rather than open-market sales. After these transactions, he held 4,121.765 common shares directly and an additional 90.269 shares indirectly through the ESOP II Trust.
Stepan Company executive Sean Thomas Moriarty reported RSU vesting transactions and related tax withholding. On March 3 and 4, 2026, restricted stock units converted into common shares per award terms, and a portion of the resulting stock was withheld to cover tax liabilities, with remaining shares increasing his direct ownership.
Stepan Company executive Sean Thomas Moriarty reported multiple equity awards and updated holdings. On March 2, 2026, he was granted 6,440 Stock Appreciation Rights, 2,247 performance shares, and 4,495 restricted stock units, each generally vesting ratably over three years beginning on that grant date.
The performance shares vest upon certification that Stepan Company meets performance goals for the period ending December 31, 2028. On February 27, 2026, he also acquired 56.765 shares of common stock at $52.51 per share as an award, bringing his direct common stock holdings to 14,205.2335 shares and his indirect holdings via the ESOP II Trust to 4,478.351 shares. A prior Form 4 incorrectly stated the Stock Appreciation Right amount and is corrected in this amendment.
Stepan Co vice president, general counsel and secretary Shawn G. Lisle reported multiple equity awards. On March 2, 2026, he received 4,495 restricted stock units, 2,247 performance shares and 6,440 stock appreciation rights, all as grants with no cash paid. On February 27, 2026, he also acquired 25.544 shares of common stock at $52.51 per share as an award. The RSUs vest in equal portions over three years, while the performance shares vest if Stepan meets specified performance goals for a period ending on December 31, 2028.
Stepan Company executive Andrea Jean Barry, VP & CHRO, reported multiple stock-based awards. On March 2, 2026, she acquired 4,495 restricted stock units, 2,247 performance shares, and 6,440 stock appreciation rights, all at a stated price of $0.00 per unit.
The RSUs vest ratably over three years starting on the grant date. The performance shares each represent one share of common stock and vest only if Stepan meets specified performance goals for a performance period ending on December 31, 2028. On February 27, 2026, she was also granted 16.464 shares of common stock at $52.51 per share.